阿立哌唑治疗首发精神分裂症的随访对照研究  

Follow-up controlled study of aripiprazole in the treatment of patients with first-episode schizophrenia

作　　者：魏长礼 穆小梅 侯宁[1] 庞润慧 颉瑞 洪贵子 

机构地区：[1]甘肃省天水市第三人民医院,741000

出　　处：《临床精神医学杂志》2011年第2期119-121,共3页Journal of Clinical Psychiatry

摘　　要：目的:探讨阿立哌唑与利培酮治疗首发精神分裂症的疗效和安全性。方法:将148例首发精神分裂症患者随机分为阿立哌唑组75例和利培酮组73例。以阳性与阴性症状量表(PANSS)减分率评定疗效同时评定社会功能缺陷筛选表(SDSS)和治疗中出现的症状量表(TESS),以SDSS评定社会功能,用TESS评定不良反应。结果:阿立哌唑组与利培酮组在痊愈率、显效率、PANSS评分与SDSS评分差异无统计学意义(P均>0.05)。阿立哌唑组在体质量增加、内分泌失调与锥体外系方面少于利培酮组,而在兴奋激越与恶心呕吐多于利培酮组,差异均具有统计学意义(P均<0.05)。结论:阿立哌唑与利培酮治疗首发精神分裂症长期疗效均好,阿立哌唑不良反应较少,依从性高。Objective： To explore the efficacy and safety of aripiprazole and risperidone in the treatment of patients with first-episode schizophrenia. Method：One hundred and forty-eight patients with first-episode schizophrenia were divided into aripiprazole group（75 cases） and risperidone group（73 cases）randomly.The ratio of the reduction of positive and negative syndrome scale（PANSS） was used to assess efficacy,while the social disability screening scale（SDSS） was used to assess social function and the treatment emergent symptom scale（TESS） was used to assess side effects. Results：The two groups showed no statistical difference in healing rate,efficiency rate,the scores of PANSS and SDSS（P0.05）.In the aspect of adverse reactions,aripiprazole group was associated with more erethism,nausea and vomit while risperidone group was associated with more weight gain,endocrinopathy and extrapyramidal syndrome（P0.05）. Conclusion：Both aripiprazole and risperidone are effective for patients with first-episode schizophrenia,but the adverse reactions of aripiprazole is fewer with good compliance.

关 键 词：精神分裂症 阿立哌唑 利培酮 随访 

分 类 号：R749.3[医药卫生—神经病学与精神病学]